Sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been used in some children with HI resistant to conventional medical therapies, based on reports of beneficial responses in adults with insulinoma [143]. The gene discussed is MTOR; the disease is pancreatic insulinoma.